Siltuximab clinical trials
Also written CNTO 328 and Sylvant.
How each study uses siltuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the siltuximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Apr 2014 · SYLVANT · BLA 125496 (FDA, Drugs@FDA)
- European Union
- 22 May 2014 · Sylvant · EMEA/H/C/003708 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 20
Centocor, Inc. (8) · Janssen Research & Development, LLC (7) · Memorial Sloan Kettering Cancer Center (2) · SWOG Cancer Research Network (2) · Recordati UK (2) · Nantes University Hospital (1) · University of Alabama at Birmingham (1) · Timothy Voorhees (1)
Often tested with
Tested in the same studies.
Interleukin 1 Receptor Antagonist Protein (1) · Tocilizumab (1) · Anti-IL-6 Monoclonal Antibody (1) · Erenumab (1) · Epcoritamab (1) · Teclistamab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test siltuximab.
- Dec 2026Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES TrialPhase 2 · Yuanquan Yang
- Oct 2027Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisPhase 2 · Memorial Sloan Kettering Cancer Center
- Nov 2027A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantPhase 2 · Memorial Sloan Kettering Cancer Center
- Nov 2027Screening Trial for Pain Relief in Schwannomatosis (STARFISH)Phase 2 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses siltuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 38
- A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06679829Written as SiltuximabHow we know
- Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES TrialRecruitingPhase 2Yuanquan YangNCT06470971Written as SiltuximabHow we know
- A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung TransplantationRecruitingPhase 1Washington University School of MedicineNCT06990711Written as SiltuximabHow we know
- Screening Trial for Pain Relief in Schwannomatosis (STARFISH)RecruitingPhase 2Massachusetts General HospitalNCT05684692Written as SiltuximabHow we know
- Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to EpcoritamabRecruitingPhase 1Taylor BrooksNCT06447376Written as SiltuximabHow we know
- A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07106671Written as SiltuximabHow we know
- Siltuximab in SchizophreniaRecruitingPhase 1/2Brian MillerNCT02796859Written as SiltuximabHow we know
- Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAMCompletedPhase 1Nantes University HospitalNCT05697510Written as SiltuximabHow we know
- Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03315026Written as SiltuximabHow we know
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell TherapyCompletedPhase 2University of Alabama at BirminghamNCT04975555Written as SiltuximabHow we know
- Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)TerminatedEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05316116Written as SiltuximabHow we know
- Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMMWithdrawnPhase 2Jack Khouri, MDNCT06352866Written as SiltuximabHow we know
- Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin LymphomaCompletedPhase 1Timothy VoorheesNCT05665725Written as SiltuximabHow we know
- Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 PneumoniaCompletedPhase 2Judit Pich MartínezNCT04329650Written as SiltuximabHow we know
- Treatment of COVID-19 Patients With Anti-interleukin DrugsCompletedPhase 3University Hospital, GhentNCT04330638Written as SiltuximabHow we know
- Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman DiseaseTerminatedPhase 2Recordati UKNCT04838860Written as SiltuximabHow we know
- SILtuximab in Viral ARds (SILVAR) StudyTerminatedPhase 3Recordati UKNCT04616586Written as SiltuximabHow we know
- A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple MyelomaCompletedPhase 2Janssen Research & Development, LLCNCT01484275Written as SiltuximabHow we know
- A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 2Janssen Research & Development, LLCNCT00401843Written as SiltuximabHow we know
- Modulation of STAT3 Signaling With Siltuximab in Type 1 DiabetesCompletedEarly Phase 1Carla Greenbaum, MDNCT02641522Written as SiltuximabHow we know
See all 38 studies that test siltuximab →
Given beside what is tested · 4 — siltuximab is usual care or a partner of the new treatment
- A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)Not yet recruitingPhase 1Merck Sharp & Dohme LLCNCT07870278Written as SiltuximabHow we know
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07709000Written as SiltuximabHow we know
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07570173Written as SiltuximabHow we know
- Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic CancerCompletedPhase 1/2Emory UniversityNCT04191421Written as SiltuximabHow we know
Codes
What other systems call siltuximab · ClinicalTrials.gg INT004818
- MeSH (NLM) C504234siltuximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) T4H8FMA7IMSILTUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 1535218Confirmed FDA, Wikidata
- Wikidata Q3960572siltuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61084SiltuximabOne source FDA
- DrugBank DB09036One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C504234 | siltuximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | T4H8FMA7IM | SILTUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1535218 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3960572 | siltuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61084 | Siltuximab | One source FDA |
| DrugBank | DB09036 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.